Starton Therapeutics Announces 100% Partial Response or Better in Multiple Myeloma Patients in Interim, Top-line Data from STAR-LLD Phase 1b Clinical Trial
June 21, 2024 08:05 ET
|
Starton Therapeutics
100% of patients enrolled achieved a partial response or betterMilder and less frequent drug-related adverse events were observed compared to those associated with Revlimid®No grade 3 or greater...
U.S. Patent and Trademark Office Grants US Patent # 11,975,112 for “Treatment of Vomiting and Nausea with Minimum Dose of Olanzapine”
May 20, 2024 10:36 ET
|
Starton Therapeutics
Olanzapine (ZYPREXA®) is an antipsychotic medication used to treat schizophrenia and bipolar disorder that is commonly used as anti-nausea off label medication.Olanzapine has been investigated for use...
Starton Therapeutics Announces Enrollment Completion for STAR-LLD Phase 1b Clinical Trial in Multiple Myeloma
April 25, 2024 08:30 ET
|
Starton Therapeutics
Phase 1b data in the first 50% of patients reflect the responses seen in animals and may suggest superiority in both safety and efficacy when compared to oral Revlimid®Anticipate FDA alignment and...
Starton Therapeutics to Present at Upcoming MedInvest and Needham Conferences
March 25, 2024 08:00 ET
|
Starton Therapeutics
PARAMUS, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc., (“Starton” or the “Company”), a clinical-stage biotechnology company focused on transforming standard-of-care therapies...
Starton Therapeutics to Present at BIO CEO & Investor Conference 2024
February 23, 2024 14:48 ET
|
Starton Therapeutics
PARAMUS, N.J., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company focused on transforming standard-of-care therapies...
Starton Therapeutics Announces Opening of Second Clinical Site for STAR-LLD Phase 1b Trial in Multiple Myeloma and Provides Study Update
February 14, 2024 13:48 ET
|
Starton Therapeutics
Regional Medical Oncology Center is activated and open to screen patientsStudy enrollment is ahead of schedule with half of the patients enrolled and complete enrollment which was previously...
Starton Therapeutics Announces STARTICLES Filing
January 17, 2024 15:12 ET
|
Starton Therapeutics
STARTICLES, referring to proprietary and novel solid-state particulates suspended within a drug-in-adhesive patch for delivery of active pharmaceutical ingredients (API) developed by Starton...
Starton Therapeutics Announces Initial Key Safety and Efficacy Signals with STAR-LLD in Patients with Relapsed or Refractory Multiple Myeloma
January 03, 2024 15:46 ET
|
Starton Therapeutics
Study enrollment is ahead of schedule with half of the patients enrolled and complete enrollment is expected by Q3/24Early data may suggest superiority in safety compared to oral Revlimid No...
Starton Therapeutics Announces the Launch of STARSILON a Novel Proprietary Transdermal PATCH Delivery Platform
January 02, 2024 14:00 ET
|
Starton Therapeutics
Novel platform technology potentially expands the number of active pharmaceutical ingredients that can be delivered transdermallyTechnology offers a unique approach to maintaining concentration...
Starton Therapeutics to Present at Biotech Showcase 2024 in San Francisco
December 18, 2023 08:00 ET
|
Starton Therapeutics
PARAMUS, N.J., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc., (the “Company”) a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary...